Immunome Announces Pricing of Public Offering of Common Stock
February 13 2024 - 10:38PM
Business Wire
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology
company dedicated to developing first-in-class and best-in-class
targeted cancer therapies, today announced the pricing of an
underwritten public offering of 10,000,000 shares of its common
stock at a price to the public of $20.00 per share. All of the
shares are to be sold by Immunome.
The gross proceeds to Immunome from the offering, before
deducting underwriting discounts and commissions and offering
expenses, are expected to be $200.0 million. In addition, Immunome
has granted the underwriters a 30-day option to purchase up to an
additional 1,500,000 shares of its common stock at the public
offering price, less underwriting discounts and commissions. The
offering is expected to close on February 16, 2024, subject to the
satisfaction of customary closing conditions.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim
Securities are acting as joint book-running managers for the
offering. Wedbush PacGrow is acting as lead manager for the
offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 that was filed with the U.S. Securities and
Exchange Commission (the "SEC") on February 13, 2024 and
automatically became effective upon filing. A preliminary
prospectus supplement and accompanying prospectus relating to the
proposed offering were filed with the SEC and are available for
free on the SEC’s website located at http://www.sec.gov. A final
prospectus supplement and accompanying prospectus relating to the
proposed offering will be filed with the SEC and will be available
for free on the SEC’s website located at http://www.sec.gov. Copies
of the final prospectus supplement and the accompanying prospectus
relating to the offering, when available, may be obtained from:
J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; Leerink
Partners LLC, Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or
by email at syndicate@leerink.com; or Guggenheim Securities, LLC
Attention: Equity Syndicate Department, 330 Madison Avenue, New
York, NY 10017 or by telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including ADCs, radioligand therapies, immunotherapies,
and small molecules. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
Forward-looking Statements
Statements contained in this press release regarding Immunome’s
expectations regarding the offering are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include
statements regarding, among other things, Immunome’s expectations
of market conditions and the satisfaction of customary closing
conditions related to the public offering, and the expected closing
of the offering and the anticipated use of proceeds therefrom.
These forward-looking statements are based upon Immunome’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, Immunome’s expectations regarding market conditions,
the satisfaction of customary closing conditions related to the
offering, Immunome's ability to complete the offering, and risks
and uncertainties inherent in Immunome’s business. These and other
risks and uncertainties are described in greater detail in the
section entitled “Risk Factors” in Immunome's most recent annual
report on Form 10-K and quarterly report on Form 10-Q filed with
the SEC, as well as discussions of potential risks, uncertainties,
and other important factors in Immunome's other filings with the
SEC, including those contained or incorporated by reference in the
preliminary prospectus supplement and accompanying prospectus
related to the offering filed with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. Immunome undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213676331/en/
Investor Contact: Max Rosett Interim Chief Financial
Officer and EVP, Operations mrosett@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Jul 2023 to Jul 2024